Novo Nordisk (NVO) Stock
Key stats
- Market cap
- $170.56B
- Price / Earnings ratio
- 9.7x
- EPS (TTM)
- $4.01
- Volume
- Loading
- 52-week high
- $64.16
- 52-week low
- $35.12
- EPS vs analyst estimate
- +33.4%Q3 FY25 · $1.03 vs $0.77
- Next earnings report
- 4 Nov 2026
Source: third-party data provider, as of October 28, 2026
EPS estimate: analyst consensus
Compare with NVO
Recent news

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
NVO

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
NVO

US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
NVO

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
NVO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.14
- MACD 12/26/9
- -0.58
- EMA 9 of MACD
- -0.89
- MACD histogram
- 0.31
- SMA 50
- $41.65
- Price below SMA 50
- EMA 50
- $41.02
- Price below EMA 50
- SMA 200
- $44.50
- Price below SMA 200
- EMA 200
- $44.42
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 27, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Sell
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.83 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
NVO

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
NVO

US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
NVO

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
NVO

GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
NVO

NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
NVO

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.
NVO

Where Will Novo Stock Be in 10 Years?
Where Will Novo Stock Be in 10 Years?
NVO

How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
NVO

Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
NVO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Maziar Mike Doustdar B.A. | President, CEO & Member of the Management Board | 1970 |
| Ms. Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board | 1986 |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board | 1971 |
| Dr. Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board | 1970 |
| Ms. Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board | 1977 |
| Ms. Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board | 1982 |
| Mr. John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board | 1972 |
| Mr. Emil Kongshoej Larsen | EVP of International Operations & Member of Management Board | 1975 |
| Mr. Jamey Millar | Executive VP of US Operations & Member of Management Board | 1968 |
| Ms. Hong Chow | Executive VP of Product & Portfolio Strategy and Member of Management Board | 1971 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of October 28, 2026
Technical indicators
- RSI 14
- 43.14
- MACD 12/26/9
- -0.58
- EMA 9 of MACD
- -0.89
- MACD histogram
- 0.31
- SMA 50
- $41.65
- Price below SMA 50
- EMA 50
- $41.02
- Price below EMA 50
- SMA 200
- $44.50
- Price below SMA 200
- EMA 200
- $44.42
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 27, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $40.00
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.0 | -2.4 | +4.4 | |||||||||
| 2022 | -8.2 | +0.4 | +7.2 | +1.0 | -3.0 | +1.0 | +4.0 | -8.6 | -4.7 | +6.1 | +17.1 | +7.3 |
| 2023 | +1.3 | +1.4 | +11.4 | +4.7 | -4.2 | +2.4 | +1.0 | +14.8 | -3.9 | +5.2 | +4.3 | +3.0 |
| 2024 | +12.4 | +3.4 | +3.4 | +0.6 | +4.7 | +5.2 | -8.8 | +5.1 | -12.6 | -5.1 | -4.6 | -20.8 |
| 2025 | -3.5 | +9.7 | -22.3 | -2.3 | +9.0 | -5.2 | -32.6 | +17.2 | -1.6 | -16.4 | +0.5 | +5.1 |
| 2026 | +13.4 | -36.5 | -2.7 | +15.7 | +3.9 | +8.8 | -3.5 | -3.7 | -16.0 | +3.4 |
Corporate actions
Upcoming
No upcoming corporate actions for NVO



